VIVE - Viveve Medical, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6150
+0.0126 (+2.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.6024
Open0.6142
Bid0.0000 x 4000
Ask0.0000 x 900
Day's Range0.5797 - 0.6250
52 Week Range0.4200 - 4.3400
Volume1,259,140
Avg. Volume549,532
Market Cap28.59M
Beta (3Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • ACCESSWIRE12 days ago

    Viveve Reports First Quarter 2019 Financial and Operating Results

    - Successful organizational realignment resulting in decreased operating expenses - Significant progress in clinical programs targeting expanded indications in sexual function and stress urinary incontinence ...

  • ACCESSWIRE20 days ago

    Viveve to Host Conference Call to Discuss First Quarter 2019 Financial and Operating Results on May 9, 2019

    ENGLEWOOD, CO / ACCESSWIRE / May 2, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2019 financial and operating results after the close of the U.S. financial markets on Thursday, May 9, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRElast month

    Viveve Announces CE Mark Clearance for its Next Generation 2.0 Platform in the European Union

    ENGLEWOOD, CO / ACCESSWIRE / April 11, 2019 / Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that the company received CE Mark clearance for its next generation Viveve 2.0 cryogen-cooled monopolar radiofrequency (CMRF) system and tips in the European Union. "As part of our ongoing regulatory strategy to expand the commercial launch of our Viveve 2.0 platform globally, we're extremely pleased that our next generation system and its consumable treatment tips are now available in over 30 countries in Europe.

  • ACCESSWIRE2 months ago

    Viveve Reports Fourth Quarter and Full Year 2018 Financial Results

    ENGLEWOOD, CO / ACCESSWIRE / March 14, 2019 / Viveve Medical Inc. (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today reported financial results for the three months ...

  • ACCESSWIRE2 months ago

    Viveve Completes Enrollment in VIVEVE II Trial

    ENGLEWOOD, CO / ACCESSWIRE / March 11, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, announced today that it has completed enrollment in its VIVEVE II trial, a multicenter, randomized, double-blinded, sham-controlled study to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of sexual function in women following vaginal childbirth. "Completion of enrollment in our VIVEVE II sexual function trial represents a tremendous milestone in our Company's quest to address an enormous unmet medical need for women. An estimated 12-14 million women worldwide suffer from diminished sexual function following vaginal childbirth.

  • ACCESSWIRE2 months ago

    Viveve to Host Conference Call to Discuss Fourth Quarter and Year-end 2018 Financial Results and Corporate Update on March 14, 2019

    ENGLEWOOD, CO / ACCESSWIRE / March 7, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report its fourth quarter and year-end 2018 financial results after the close of the U.S. financial markets on Thursday, March 14, 2019, and will host a live conference call and webcast at 5:00 PM ET the same day. A recording of the webcast will be posted on the company's investor relations website following the call at ir.viveve.com and will be available online for 90 days. Viveve Medical, Inc. is a medical technology company focused on women's intimate health.

  • ACCESSWIRE3 months ago

    Viveve to Present at Cowen and Company 39th Annual Health Care Conference

    ENGLEWOOD, CO / ACCESSWIRE / March 5, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Cowen and Company 39th Annual Health Care Conference. Mr. Durbin will also meet with members of the investment community during one-on-one meetings at the conference. The presentation will be webcast live on the Investors section of the Company's website at ir.viveve.com.

  • GlobeNewswire4 months ago

    Viveve Reports Preliminary Full Year 2018 Financial Results, Announces 2019 Revenue Guidance and Provides Corporate Update

    Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019. The company also announced it has implemented changes to the Viveve organization to reduce operating expenses and focus on label expansion and market development for its cryogen-cooled monopolar radiofrequency (CMRF) technology.

  • GlobeNewswire5 months ago

    Viveve Completes Enrollment in LIBERATE-International Trial for Improvement of Stress Urinary Incontinence

    “As we seek to achieve regulatory clearances for our CMRF technology for the treatment of SUI, a condition that affects an estimated 25-30 million women worldwide, completion of enrollment in the LIBERATE-International trial is an important milestone,” stated Scott Durbin, chief executive officer and director of Viveve. “Our single-session procedure offers women the potential for significant improvement in urine leakage and the ability to engage in their daily lives with greater comfort and control. LIBERATE-International is a multicenter, randomized, double-blinded, and sham-controlled trial with an enrollment of approximately 100 subjects at up to ten study sites in Canada.

  • GlobeNewswire5 months ago

    Viveve Announces FDA Clearance to Advance VIVEVE II Clinical Study to Full Enrollment

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency determined that the company provided sufficient data to support continued subject enrollment in the trial and that there are no safety concerns that preclude the continuation of the study.

  • GlobeNewswire5 months ago

    Viveve Announces Closing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the closing of its previously announced underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The net proceeds to Viveve from the offering were approximately $18.8 million, after deducting underwriting discounts and commissions (but before deducting estimated offering expenses payable by the Company). Viveve intends to use the net proceeds from this offering to support the continued commercialization of its products in North America and internationally, to obtain additional regulatory clearances and to conduct the VIVEVE II Sexual Function and LIBERATE – International and LIBERATE – U.S. stress urinary incontinence (SUI) clinical trials, and for general corporate and working capital purposes.

  • GlobeNewswire5 months ago

    Viveve Announces Pricing of Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock at a public offering price of $1.50 per share. The gross proceeds to Viveve from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Viveve, are expected to be $20.0 million. All shares of common stock are being offered by Viveve.

  • GlobeNewswire5 months ago

    Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study

    Viveve Medical, Inc. (VIVE) (“Viveve”), a medical technology company focused on women's intimate health, today announced positive 12-month data from an investigator-initiated, single-arm, 12-month feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. The study was conducted by Bruce Allan, PhD, MD, FRCS(C), founder and medical director of the Allan Centre in Calgary, Alberta. “These positive results build upon the demonstrated effectiveness and durability of our single-session CMRF treatment for women experiencing SUI symptoms, as previously reported in the six-month interim data from this feasibility study, as well as the 12-month data in the separate SUI pilot study,” said Scott Durbin, chief executive officer and director of Viveve.

  • GlobeNewswire5 months ago

    Viveve Announces Proposed Public Offering of Shares of Common Stock

    Viveve Medical, Inc. (“Viveve”) (VIVE), a medical technology company focused on women’s intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be offered by Viveve. Viveve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock in connection with the public offering.

  • GlobeNewswire6 months ago

    Viveve to Host Stress Urinary Incontinence Symposium with Physician Opinion Leaders

    The live webcast of this event can be accessible through the company’s investor relations website at http://ir.viveve.com. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. In the second quarter of 2018, Viveve initiated VIVEVE II, a multicenter, randomized, double-blind, sham-controlled study to assess improvement of sexual function in women following childbirth following an Investigational Device Exemption (IDE) application approval from the U.S. Food and Drug Administration (FDA) in March of 2018.

  • GlobeNewswire6 months ago

    New Research Coverage Highlights Chuy's, Viveve Medical, ClearSign Combustion, WhiteHorse Finance, Crinetics Pharmaceuticals, and Boston Omaha — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire6 months ago

    Viveve Named One of North America’s 500 Fastest Growing Companies by Deloitte

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that the company has been included in Deloitte’s 2018 Technology Fast 500, a list of the 500 fastest growing technology, media, telecommunications, life sciences, and energy technology companies in North America. “We are proud to be acknowledged as the only medical device company listed among the top ten companies named to the 2018 Technology Fast 500 list. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.

  • GlobeNewswire6 months ago

    Viveve to Present at Stifel 2018 Healthcare Conference

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that Scott Durbin, chief executive officer and director, will present at the Stifel 2018 Healthcare Conference on Tuesday, November 13th at 8:45 AM ET in New York City. Mr. Durbin will provide an update on the company's development strategies and commercialization efforts in the United States and abroad.

  • GlobeNewswire6 months ago

    Viveve Reports Third Quarter 2018 Financial Results

    Continued commercial growth for Viveve® System including record quarter of treatment tip sales Significant advancement of clinical programs targeting new indications in.

  • GlobeNewswire7 months ago

    Viveve to Host Conference Call to Discuss Third Quarter 2018 Financial and Operating Results

    Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it will report financial results for the third quarter ended September 30, 2018 after the close of the U.S. financial markets on Thursday, November 8, 2018. Management will host a live conference call and webcast to discuss these results and provide an update on corporate and commercial developments on Friday, November 9, 2018 at 8:00am ET. Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life.